Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

​Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.

The post Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.